Clinical Trial Detail

NCT ID NCT03219333
Title A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv

Age Groups: adult senior

No variant requirements are available.